Avidity NanoMedicines has announced the issuance of two new U.S. patents. ARCs™ combine the potency and specificity of biologics with a nucleic acid-based payload, representing a breakthrough approach to the targeted delivery of nucleic acid-based medicines.
The two new U.S. patents arose out of pioneering work conducted by Professor Mark Davis and colleagues at Caltech and are exclusively licensed to Avidity NanoMedicines.
U.S. Patent 8,557,292, entitled "Carrier nanoparticles and related compositions, methods and systems," contains broad claims covering the novel nanoparticles and their components, as well as methods for making and using them.
U.S. Patent 8,746,999 contains broad claims covering both the types of targeting ligands, and the types of nucleic acid payloads in ARCs™, as well as methods for making and using them.
Together, these two new U.S. patents provide a foundation for the intellectual property portfolio covering the ARC™ technology as well as the products enabled by the approach.
"Professor Mark Davis has been at the scientific forefront of nanomedicines for nearly 20 years," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Avidity NanoMedicines.
Wilson continued, "On behalf of everyone at Avidity, we are thrilled to be building on Mark's pioneering contributions as we advance ARCs™ as a new class of targeted, nucleic acid-based medicines."